Malaria is common in areas such as Africa, South America, and Southern Asia. This medicine is not effective against all strains of malaria. Plaquenil for plaque Sideeffects of plaquenil Pantziarka P et al 2014 The Repurposing Drugs in Oncology ReDO project Ecancer Medical Science 8 442 PMID 25075216 PMCID 4096030. 139. Buch I et al 2016 Schedule-dependent synergy of chloroquine with chemotherapy for anti-cancer treatment Cancer Research and Oncology Open Access 22 140. Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma Article PDF Available in The Oncologist 196 May. Wolpin BM, Rubinson DA, Wang X, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 2014;7–8. Taking hydroxychloroquine long-term or at high doses may cause irreversible damage to the retina of your eye. Hydroxychloroquine is also an antirheumatic medicine and is used to treat symptoms of rheumatoid arthritis and discoid or systemic lupus erythematosus. Wolpin oncologist 2014 hydroxychloroquine A randomised phase II trial of hydroxychloroquine and., PDF Phase II and Pharmacodynamic Study of Autophagy. Plaquenil heat Wolpin BM, Rubinson DA, Wang X, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 2014; 196 637-8. Inhibition of Autophagy by Targeting ATG4B Promises and.. The clinical value of using chloroquine or hydroxychloroquin.. Hydroxychloroquine An old drug with new relevance.. Brian M. Wolpin is supported by NIH Grant K07 CA140790 from the National Cancer Institute, an American Society of Clinical Oncology Career Development Award, a Howard Hughes Medical Institute Early Career Physician‐Scientist Award, the Lustgarten Foundation, and Promises for Purple. Blocking autophagy with hydroxychloroquine hCQ augments cell death associated with alkylating chemotherapy in preclinical models. This phase i study evaluated the maximum tolerated dose MTD, safety, preliminary activity, phar-macokinetics, and pharmacodynamics of CQ in combination with dose-intense temozolomide TMZ in patients with h Dr. Wolpin is a medical oncologist who sees patients within and serves as director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute DFCI. His research program is dedicated to investigation of pancreatic ductal adenocarcinoma PDAC biology and treatment.